TESAMORELIN
Tesamorelin is a synthetic 44–amino acid peptide analog of human GHRH, designed to stimulate the pituitary gland to release growth hormone (GH). It contains a trans-3-hexenoic acid modification at the N-terminal to increase stability and protect against enzymatic degradation, resulting in a longer half-life compared to native GHRH.
A synthetic growth hormone–releasing hormone (GHRH) analog modeled for laboratory research.
Tesamorelin is a synthetic 44–amino acid peptide analog of human GHRH, designed to stimulate the pituitary gland to release growth hormone (GH). It contains a trans-3-hexenoic acid modification at the N-terminal to increase stability and protect against enzymatic degradation, resulting in a longer half-life compared to native GHRH.
In research, Tesamorelin is studied for its ability to elevate and sustain GH and insulin-like growth factor-1 (IGF-1) levels, with applications in models of metabolic regulation, body composition improvement, and recovery from catabolic states.
Titan research and immune system function
Growth Hormone Stimulation:
Studied for increasing pulsatile GH release in controlled research models.
IGF-1 Elevation:
Investigated for its effects on circulating IGF-1, impacting protein synthesis and recovery.
Body Composition Research:
Explored for its role in reducing visceral adipose tissue and preserving lean muscle.
Metabolic Function:
Studied in models evaluating glucose metabolism, lipid profiles, and insulin sensitivity.
Anti-Catabolic Effects:
Assessed for its potential to counteract muscle wasting in various experimental conditions.
Titan research and immune system function
Pituitary Stimulation:
Directly activates GHRH receptors in the anterior pituitary to promote GH release.
Visceral Fat Reduction:
Research shows selective reduction in deep abdominal fat while sparing subcutaneous stores.
Metabolic Regulation:
May improve insulin sensitivity and lipid metabolism in certain models.
(1) Stanley, T. L., et al. (2011). Effects of Tesamorelin on visceral fat and metabolic parameters in HIV-infected patients with abdominal fat accumulation. → Found a mean 48–65% increase in IGF-1 levels by week 4.[Journal of Clinical Endocrinology & Metabolism, 96(2), 550–558]
(2) Falutz, J., et al. (2007). Effects of Tesamorelin, a growth hormone-releasing factor analogue, in patients with HIV-associated lipodystrophy. → Confirmed IGF-1 and GH axis stimulation in a dose- and time-dependent manner.
(3) Administration Guidelines, Theratechnologies Inc. (2020). → Indicates elevated IGF-1 within 7 days, with levels continuing to rise through weeks 2–4 with continued dosing.
.svg)
The graph shows the effect of Tesamorelin on IGF-1 levels over a four-week period, based on human clinical data. At Week 1, IGF-1 levels increase by 20%, showing an early and noticeable impact. By Week 2, the rise accelerates to 45%, reflecting a strong upward trend.
By Week 4, IGF-1 levels reach 65% above baseline, demonstrating a substantial improvement. The results suggest Tesamorelin provides fast and progressive benefits, making it effective for boosting IGF-1 within a relatively short timeframe.
Form:
Lyophilized Powder
Storage (unreconstituted):
- Store at 2–8 °C (refrigerated), protected from light.
- For long-term storage, keep at –20 °C.
- Avoid repeated freeze–thaw cycles.
Reconstitution:
- Reconstitute with sterile water for injection or 0.9% NaCl immediately prior to use. Use aseptic technique.
Storage (after reconstitution):
- Store at 2–8 °C.
- Use within 7–10 days.
- Discard any unused solution after this period.
- Handle under sterile conditions.
- Do not shake vigorously (may cause peptide denaturation).
- Inspect visually for particulate matter or discoloration before use.
Issued for quality verification of tested material.
Feedback highlighting proven outcomes and reliability.
